NASD · Healthcare · Drug Manufacturers - Specialty & Generic · Germany
Evotec SE ADR is a small cap company (market value between $300 million and $2 billion) in the Drug Manufacturers - Specialty & Generic industry.
Intrinsic value, DCF valuation, financial health and value investing analysis for the Evotec SE ADR stock.
Overvalued: intrinsic value $0.96 per share, market price $1.53, margin of safety -59.4% (as of 2026-10-30).
Its through-the-cycle earnings (2.8% median margin), capitalised at 10.5% with no growth, values the shares at $0.96; the price of $1.53 is 59% above that value.
Leak Score: 31/100 on 8 of 12 signals (On Watch).
All 84 Drug Manufacturers - Specialty & Generic stocks
19 more in this industry show a wider margin of safety.
EVO is overvalued (as of the 2026-10-30 close). Its through-the-cycle earnings (2.8% median margin), capitalised at 10.5% with no growth, values the shares at $0.96; the price of $1.53 is 59% above that value.
$0.96 per share (as of the 2026-10-30 close), against a market price of $1.53. That is a margin of safety of -59.4%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
31 out of 100, which we rate "On Watch", on 8 of 12 value investing signals.